𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia

✍ Scribed by Okur, Fatma Visal; Yvon, Eric; Biagi, Ettore; Dotti, Gianpietro; Carrum, George; Heslop, Helen; Mims, Martha P.; Fratantoni, Joseph C.; Peshwa, Madhusudan V.; Li, Linhong

Book ID
115488017
Publisher
Informa plc
Year
2011
Tongue
English
Weight
428 KB
Volume
13
Category
Article
ISSN
1465-3249

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Clinical relevance of the expression of
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia
✍ Sherif Ibrahim; Iman Jilani; Susan O'Brien; Anna Rogers; Taghi Manshouri; Franci πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 532 KB

## Abstract ## BACKGROUND CD31 (platelet endothelial cell adhesion molecule‐1 [PECAM‐1]) is the ligand for CD38, a transmembrane glycoprotein that is expressed on the surface of leukemic cells in many patients with B‐cell chronic lymphocytic leukemia (B‐CLL). In a previous study, the authors showe

Prognostic value of plasma interleukin-6
Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia
✍ Raymond Lai; Susan O'Brien; Taghi Maushouri; Anna Rogers; Hagop Kantarjian; Mich πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 78 KB πŸ‘ 1 views

## Background: Interleukin 6 (il-6) is a b-cell growth and differentiation factor, which may promote the growth of b-cell neoplasms. in chronic lymphocytic leukemia (cll) patients, il-6 plasma levels increased in a stage-dependent manner, suggesting that il-6 may be a useful prognostic marker. the